Sector: Health Care
Director information for PTC THERAPEUTICS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Allan Jacobson, Ph.D. | Director | 80 | ["Co-founder of PTC Therapeutics, Inc.","Former Chairman of PTC Therapeutics Board from 1998 to 2004.","Chairman of the Department of Microbiology and Physiological Systems at the University of Massachusetts Chan Medical School.","Gerald L. and Zelda S. Haidak Professor of Cell Biology.","Co-founded Applied bioTechnology, Inc.","Special limited partner at Euclid Partners."] | ["Development Committee (Chair)"] | 2026 |
| David P. Southwell | President, Chief Executive Officer and Director | 65 | ["President, Chief Executive Officer and Director of Volastra Therapeutics.","Former Chief Executive Officer of TScan Therapeutics, Inc.","Former President and Chief Executive Officer of Inotek Pharmaceuticals, Inc.","Former Executive Vice President and Chief Financial Officer of Human Genome Sciences, Inc.","Former Executive Vice President and Chief Financial Officer of Sepracor, Inc.","Experience in investment banking with Lehman Brothers Inc.","extensive executive leadership experience","knowledge of our industry","B.A. from Rice University","M.B.A. from the Tuck School of Business at Dartmouth College"] | ["Audit Committee","Compensation Committee"] | 2026 |
| Emma Reeve | Director | 65 | ["Senior Vice President and Chief Financial Officer of Constellation Pharmaceuticals, Inc.","Treasurer of Constellation Pharmaceuticals, Inc.","Secretary of Constellation Pharmaceuticals, Inc.","Corporate Controller of Parexel International","Interim Chief Financial Officer and corporate controller of Parexel","Head of Finance and Administration at Novartis Pharma Schweiz","Vice President, Global Head Business Planning and Analysis for Novartis Vaccines and Diagnostics","Chief Financial Officer of Inotek Pharmaceuticals, Inc.","Chief Financial Officer of Aton Pharma, Inc.","Operational and finance roles at Merck Research Laboratories and Bristol Myers Squibb Company","Board of directors of Whitehawk Therapeutics, Inc.","Board of directors of Editas Medicine, Inc.","B.Sc. degree in computer science from Imperial College, University of London","Associate of the Institute of Chartered Accountants in England & Wales"] | ["Audit Committee (Chair)","Compensation Committee"] | 2026 |
| Eric Pauwels | Chief Business Officer | 65 | ["40 years of healthcare experience in biopharmaceuticals and medical devices","Senior Vice President and General Manager of the Americas since March 2015","Former Chief Commercial Officer and President of International for NPS Pharmaceuticals","Former Chief Marketing Officer of Accuray Inc.","First Chief Commercial Officer for Shire Human Genetic Therapies","B.S. from California State Polytechnic University in Pomona, California"] | [] | 2026 |
| Glenn D. Steele Jr., M.D., Ph.D. | Chairman of the Compensation Committee | 81 | ["Chairman of xG Health Solutions","President and CEO of Geisinger Health System","Dean of the Biological Sciences Division and the Pritzker School of Medicine","Vice President for Medical Affairs at the University of Chicago","Richard T. Crane Professor in the Department of Surgery","William V. McDermott Professor of Surgery at Harvard Medical School","President and CEO of Deaconess Professional Practice Group","Chairman of the Department of Surgery at New England Deaconess Hospital","Board member of Wellcare Health Plans Inc."] | ["Compensation Committee","Development Committee"] | 2026 |
| Jerome B. Zeldis | Member of Nominating and Corporate Governance Committee Development Committee | 76 | ["Executive Vice President and Head of Research and Development of NexImmune, Inc.","Chief Medical Officer of Sorrento Therapeutics, Inc.","Chief Medical Officer of Celularity, Inc.","Chief Executive Officer of Celgene Global Health","Chief Medical Officer of Celgene Corporation"] | ["Nominating and Corporate Governance Committee","Development Committee"] | 2026 |
| Jessica Chutter | Director | 65 | ["40 years experience in healthcare investment banking","Managing Director at Morgan Stanley","Vice Chair of Healthcare Investment Banking","Chair of Biotechnology Investment Banking","Experience advising biotechnology companies and pharmaceutical companies"] | [] | 2026 |
| Mary Smith | Vice Chair at the VENG Group | 63 | ["Executive leadership experience","Vice Chair at the VENG Group","Principal Deputy Director at Indian Health Service","Deputy Director at Indian Health Service","Special Counsel & Estate Trust Officer at the Office of Special Deputy Receiver Chicago Illinois","General Counsel at the Illinois Department of Insurance","Counselor at the United States Department of Justice, Civil Division","Associate Director of Policy Planning in the Domestic Policy Council","Associate Counsel to the U.S. President"] | ["Audit Committee","Compensation Committee"] | 2026 |
| Matthew B. Klein, M.D., M.S., F.A.C.S. | Director | 54 | ["Chief Executive Officer at the Company","Global Head Gene and Mitochondrial Therapies","Chief Development Officer","Chief Operating Officer","Previous CEO of BioElectron"] | ["Development Committee"] | 2026 |
| Michael Schmertzler | Chair of the Board; Court-Appointed Director | 74 | ["Chair of the Board since 2004","Adjunct Professor and Lecturer in Economics at Yale University","Visiting Professor at Yale NUS in Singapore from 2018 to 2025","Charter Trustee of Phillips Academy Andover","Executive Chairman of SHY Therapeutics","Executive Chairman of Berryville Holdings and Dispel LLC","Director of AgNovos","Managing Director of Aries Advisors, LLC","Co-Head of United States and Canadian Private Equity at Credit Suisse First Boston","Various management positions with Morgan","Extensive experience as an investment banking and financial professional","Extensive personal knowledge of the industry","Many years of service as a director"] | ["Compensation Committee","Nominating and Corporate Governance Committee","Development Committee"] | 2026 |
| Ms. Young | Director | 47 | ["more than 20 years of experience in healthcare and biotech equity research and investing","Chief Financial Officer of Bicycle Therapeutics PLC","Chief Financial Officer of Graphite Bio, Inc.","senior biotech analyst and head of research at Cantor Fitzgerald","senior biotech analyst positions at Credit Suisse","senior biotech analyst positions at Deutsche Bank","research policy analyst and president at Marwood Group","experience serving on the board of directors for BUILD NYC","serving on the board of directors of Pacira BioSciences, Inc.","B.A. in Economics and Spanish from Duke University"] | ["Audit Committee","Nominating & Corporate Governance Committee"] | 2026 |
| Neil Almstead | ["research","supply chain","technical operations","manufacturing","facilities"] | [] | 2026 | ||
| Neil Almstead, Ph.D. | Chief Technical Operations Officer | 59 | ["Chief Technical Operations Officer since December 2018","Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018","Senior Vice President, Research and CMC from July 2008 to December 2014","Senior Vice President, Chemistry and CMC from January 2007 to June 2008","Project Manager at Procter & Gamble Company","Co-authored more than 75 publications and patents pertaining to genetic disorders, oncology and inflammatory diseases","B.S. from Clarkson University","Ph.D. in Organic Chemistry from the University of Illinois at Urbana-Champaign"] | [] | 2026 |
| Stephanie S. Okey | Chair of Nominating and Corporate Governance Committee | 66 | ["over 25 years in the biopharmaceutical industry","served in various positions at Genentech, Inc.","management experience at Genzyme","Senior Vice President, Head of North America, Rare Diseases","General Manager, Rare Diseases","Vice President and General Manager, U.S. Genetic Diseases Business Unit"] | ["Nominating and Corporate Governance Committee"] | 2026 |
